Assignment/News Editors/Medical Reporters
The National Institutes of Health (NIH) is conducting a nationwide study on the safety and effectiveness of chelation therapy, an investigational treatment for people with heart disease. Chelation therapy uses a man-made amino acid, called EDTA (ethylene diamine tetra-acetic acid), which is added to the blood through a vein. For many years, people with heart disease have considered chelation therapy, despite a lack of definitive evidence. The NIH study is the largest clinical study to be conducted on chelation therapy. It is 20 times larger than any previous study and is designed to provide the answer to this important question. Results are expected in about 5 years.
More than 100 medical institutions across the country have been selected to take part in the study. You are receiving this advisory because there is a participating local site near you. For an up-to-date list of participating sites, please visit nccam.nih.gov/chelation/.
This video package is produced for the National Center for Complementary and Alternative Medicine, part of the NIH, and is for free and unrestricted use in whole or part. It includes B-roll and soundbites, footage of chelation therapy and laboratory research, and soundbites with Principal Investigator Dr. Gervasio Lamas, Investigator Dr. Roy Heilbron, and chelation study participants Edward Grocki and Julio Kaufman. To view a video clip of this package, go to: NewsBroadcastNetwork.com or nccam.nih.gov/chelation.
Wednesday, December 8, 2004
1:00–1:15 p.m., ET
Via Satellite C-Band, IA-6
Downlink: 4020 H
Audio: 6.2 - 6.8
Technical Info DURING FEED ONLY: NBN, TOC, 212-684-8910, x 221
Free From News Broadcast Network: 212-684-8910
Hard Copy Information: Tom Hendrick, 301-229-4894
Editorial Contact: NCCAM Press Office, 301-496-7790